Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
1(8%)
Results Posted
20%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
1
8%
Ph phase_1
3
25%
Ph phase_3
7
58%

Phase Distribution

3

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
7(63.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
90.9%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (27.3%)
Phase 21 (9.1%)
Phase 37 (63.6%)

Trials by Status

terminated18%
active_not_recruiting18%
completed1083%

Recent Activity

1 active trials
Showing 5 of 12
active_not_recruitingphase_3

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

NCT01252953
completed

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

NCT02931188
completedphase_3

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

NCT01860729
completedphase_3

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

NCT01524289
completedphase_3

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

NCT00685776
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01252953Phase 3

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Active Not Recruiting
NCT02931188

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

Completed
NCT01860729Phase 3

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Completed
NCT01524289Phase 3

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Completed
NCT00685776Phase 3

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Completed
NCT01760460Phase 3

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Completed
NCT01824238Phase 3

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Completed
NCT01114490Phase 1

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Completed
NCT01122667Phase 1

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Completed
NCT00990808Phase 1

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Completed
NCT01841684Phase 3

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Terminated
NCT00977288Phase 2

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12